Literature DB >> 14567969

Genotypic determinants of phenotype in North American patients with erythropoietic protoporphyria.

Hiba Risheg1, Fu-Ping Chen, Joseph R Bloomer.   

Abstract

Erythropoietic protoporphyria (EPP) is characterized by excess accumulation of protoporphyrin, which is due to deficient activity of the enzyme ferrochelatase (FECH). This results in photosensitivity and in some patients liver disease which may necessitate liver transplantation. The aim of this study was to delineate the abnormalities in the FECH gene which cause phenotypic expression in EPP. We identified 43 individuals from 25 North American families with EPP who were heterozygous for various FECH mutations, but the mutations did not adequately explain the variable phenotype. We also examined the presence of an intron polymorphism (IVS3-48c) in the FECH gene which was shown to cause the formation of aberrantly spliced FECH mRNA. FECH DNA analysis demonstrated that 94% of 31 symptomatic individuals with FECH mutations were heterozygous for IVS3-48c, whereas 12 asymptomatic individuals with FECH mutations were homozygous for IVS3-48t. Haplotype analysis in four families showed that symptomatic members had the IVS3-48c polymorphism in the non-mutant FECH allele. Sequencing of the proximal FECH gene promoter showed no additional changes which might affect gene expression. The levels of normal FECH mRNA, measured by relative quantitative RT-PCR, and FECH enzyme activity were correspondingly lower in the cultured lymphoblasts of family members with the IVS3-48c polymorphism. These results indicate that symptomatic disease in most North American patients with EPP is explained by the inheritance of a mutation in one FECH allele which causes a structural alteration in the protein, together with a low expressing non-mutant FECH allele which is caused by the IVS3-48c polymorphism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567969     DOI: 10.1016/j.ymgme.2003.07.001

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  9 in total

1.  Strong correlation of ferrochelatase enzymatic activity with Mitoferrin-1 mRNA in lymphoblasts of patients with protoporphyria.

Authors:  John Phillips; Collin Farrell; Yongming Wang; Ashwani K Singal; Karl Anderson; Manisha Balwani; Montgomery Bissell; Herbert Bonkovsky; Toni Seay; Barry Paw; Robert Desnick; Joseph Bloomer
Journal:  Mol Genet Metab       Date:  2018-10-22       Impact factor: 4.797

2.  Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria.

Authors:  Vincent Oustric; Hana Manceau; Sarah Ducamp; Rima Soaid; Zoubida Karim; Caroline Schmitt; Arienne Mirmiran; Katell Peoc'h; Bernard Grandchamp; Carole Beaumont; Said Lyoumi; François Moreau-Gaudry; Véronique Guyonnet-Dupérat; Hubert de Verneuil; Joëlle Marie; Herve Puy; Jean-Charles Deybach; Laurent Gouya
Journal:  Am J Hum Genet       Date:  2014-03-27       Impact factor: 11.025

3.  Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria.

Authors:  Yongming Wang; Nathaniel B Langer; George C Shaw; Guang Yang; Liangtao Li; Jerry Kaplan; Barry H Paw; Joseph R Bloomer
Journal:  Exp Hematol       Date:  2011-05-11       Impact factor: 3.084

4.  Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria.

Authors:  Laurent Gouya; Caroline Martin-Schmitt; Anne-Marie Robreau; Frederic Austerlitz; Vasco Da Silva; Patrick Brun; Sylvie Simonin; Said Lyoumi; Bernard Grandchamp; Carole Beaumont; Herve Puy; Jean-Charles Deybach
Journal:  Am J Hum Genet       Date:  2005-11-15       Impact factor: 11.025

5.  Novel null-allele mutations and genotype-phenotype correlation in Argentinean patients with erythropoietic protoporphyria.

Authors:  Victoria E Parera; Rita H Koole; Gardi Minderman; Annie Edixhoven; Maria V Rossetti; Alcira Batlle; Felix W M de Rooij
Journal:  Mol Med       Date:  2009-08-12       Impact factor: 6.354

6.  Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria.

Authors:  Manisha Balwani; Dana Doheny; David F Bishop; Irina Nazarenko; Makiko Yasuda; Harry A Dailey; Karl E Anderson; D Montgomery Bissell; Joseph Bloomer; Herbert L Bonkovsky; John D Phillips; Lawrence Liu; Robert J Desnick
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

Review 7.  Liver transplantation in the management of porphyria.

Authors:  Ashwani K Singal; Charles Parker; Christine Bowden; Manish Thapar; Lawrence Liu; Brendan M McGuire
Journal:  Hepatology       Date:  2014-07-29       Impact factor: 17.425

8.  Level of expression of the nonmutant Ferrochelatase allele is a determinant of biochemical phenotype in a mouse model of erythropoietic protoporphyria.

Authors:  Joseph Bloomer; Yongming Wang; Dongquan Chen
Journal:  Gene Regul Syst Bio       Date:  2008-05-29

Review 9.  Erythropoietic protoporphyria.

Authors:  Mario Lecha; Hervé Puy; Jean-Charles Deybach
Journal:  Orphanet J Rare Dis       Date:  2009-09-10       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.